CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS FOR STAKEHOLDERS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. KEY FINDINGS OF THE STUDY
2.2. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.2.2.1. TOP WINNING STRATEGIES, BY YEAR, 2015-2017
3.2.2.2. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2015-2017 (%)
3.2.2.3. TOP WINNING STRATEGIES, BY COMPANY, 2015-2017

3.3. PORTERS FIVE FORCES ANALYSIS

3.3.1. Bargaining power of buyers
3.3.2. Bargaining power of suppliers
3.3.3. Threat of substitutes
3.3.4. Threat of new entrants
3.3.5. Competitive rivalry

3.4. TOP PLAYER POSITIONING, 2016
3.5. MARKET DYNAMICS

3.5.1. Drivers

3.5.1.1. Increase in government expenditure for the healthcare sector
3.5.1.2. Increased access to medical insurance
3.5.1.3. Increase in geriatric population
3.5.1.4. Increase in prevalence of cancer diseases

3.5.2. Restraint

3.5.2.1. Risk of allergic reaction and limitations of the engineered T cells treatment
3.5.2.2. Stringent government regulations
3.5.2.3. High cost of engineered T cells treatment

3.5.3. Opportunity

3.5.3.1. Increase in R&D in engineered T cells
3.5.3.2. Lucrative opportunities from emerging economies

CHAPTER 4 ENGINEERED T CELLS MARKET, BY TYPE

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. CHIMERIC ANTIGEN RECEPTOR (CAR) MODIFIED T CELLS

4.2.1. Key market trends and opportunities
4.2.2. Market size and forecast

4.3. T CELLS RECEPTOR (TCR) MODIFIED T CELLS

4.3.1. Key market trends and opportunities
4.3.2. Market size and forecast

4.4. TUMOR INFILTRATING LYMPHOCYTES

4.4.1. Key market trends and opportunities
4.4.2. Market size and forecast

CHAPTER 5 ENGINEERED T CELLS MARKET, BY APPLICATION

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. LUNG CANCER

5.2.1. Market size and forecast

5.3. BREAST CANCER

5.3.1. Market size and forecast

5.4. COLORECTAL CANCER

5.4.1. Market size and forecast

5.5. MELANOMA

5.5.1. Market size and forecast

5.6. LEUKEMIA

5.6.1. Market size and forecast

5.7. OTHERS APPLICATIONS

5.7.1. Market size and forecast

CHAPTER 6 ENGINEERED T CELLS MARKET, BY END USER

6.1. OVERVIEW

6.1.1. Market size and forecast

6.2. HOSPITALS

6.2.1. Market size and forecast

6.3. CANCER RESEARCH CENTERS

6.3.1. Market size and forecast

6.4. CLINICS

6.4.1. Market size and forecast

CHAPTER 7 ENGINEERED T CELLS MARKET, BY REGION

7.1. OVERVIEW

7.1.1. Market size and forecast

7.2. NORTH AMERICA

7.2.1. Key market trends and opportunities
7.2.2. Market size and forecast
7.2.3. U.S. market size and forecast
7.2.4. Canada market size and forecast
7.2.5. Mexico market size and forecast

7.3. EUROPE

7.3.1. Key market trends and opportunities
7.3.2. Market size and forecast
7.3.3. Germany market size and forecast
7.3.4. France market size and forecast
7.3.5. UK market size and forecast
7.3.6. Italy market size and forecast
7.3.7. Spain market size and forecast
7.3.8. Rest of Europe market size and forecast

7.4. ASIA-PACIFIC

7.4.1. Key market trends and opportunities
7.4.2. Market size and forecast
7.4.3. Japan market size and forecast
7.4.4. China market size and forecast
7.4.5. India market size and forecast
7.4.6. Australia market size and forecast
7.4.7. South Korea market size and forecast
7.4.8. Taiwan market size and forecast
7.4.9. Rest of Asia-Pacific market size and forecast

7.5. LAMEA

7.5.1. Key market trends and opportunities
7.5.2. Market size and forecast
7.5.3. Brazil market size and forecast
7.5.4. Turkey market size and forecast
7.5.5. Saudi Arabia market size and forecast
7.5.6. South Africa market size and forecast
7.5.7. Rest of LAMEA market size and forecast

CHAPTER 8 COMPANY PROFILES

8.1. AUTOLUS LIMITED

8.1.1. Company overview
8.1.2. Company snapshot

8.2. BELLICUM PHARMACEUTICALS, INC.

8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Clinical trials
8.2.4. Business performance
8.2.5. Key strategic moves and developments

8.3. CELL MEDICA LIMITED

8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Clinical trials
8.3.5. Key strategic moves and developments

8.4. ELI LILLY AND COMPANY

8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Clinical trials
8.4.5. Business performance
8.4.6. Key strategic moves and developments

8.5. GILEAD SCIENCES, INC. (KITE PHARMA INC.)

8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Clinical trials
8.5.5. Business performance

8.6. JUNO THERAPEUTICS, INC.

8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Clinical trials
8.6.4. Business performance
8.6.5. Key strategic moves and developments

8.7. NOVARTIS AG

8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Clinical trials
8.7.5. Business performance

8.8. OXFORD BIOMEDICA PLC

8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Clinical trials
8.8.5. Business performance

8.9. PFIZER INC.

8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Clinical trials
8.9.5. Business performance

8.10. PRECISION BIOSCIENCES INC.

8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Key strategic moves and developments